N-(3-(2-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)-2-mercaptoacetamide | 1141401-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(3-(2-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)-2-mercaptoacetamide
• 英文别名: 2-Mercaptoacetamide, 12f；2-sulfanyl-N-[5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]acetamide
• CAS: 1141401-98-0
• 化学式: C₁₂H₁₀F₃N₃OS
• 分子量: 301.292
• InChiKey: ZBBUSWWGEUKZPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(2-(trifluoromethyl)phenyl)-1H-pyrazol-5-amine 、 巯基乙酸 以 甲苯 为溶剂， 以34%的产率得到N-(3-(2-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)-2-mercaptoacetamide
  参考文献：
  名称：

  Botulinum neurotoxin serotype A inhibitors: Small-molecule mercaptoacetamide analogs

  摘要：

  Botulinum neurotoxin elicits its paralytic activity through a zinc-dependant metalloprotease that cleaves proteins involved in neurotransmitter release. Currently, no drugs are available to reverse the effects of botulinum intoxication. Herein we report the design of a novel series of mercaptoacetamide small-molecule inhibitors active against botulinum neurotoxin serotype A. These analogs show low micromolar inhibitory activity against the isolated enzyme. Structure-activity relationship studies for a series of mercaptoacetamide analogs of 5-amino-3-phenylpyrazole reveal components essential for potent inhibitory activity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.03.013

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT DE TRAITER DES MALADIES DÉPENDANT DE MÉTALLOPROTÉASES À ZINC MATRICIELLES
  申请人：ABSOLUTE SCIENCE INC

  公开号：WO2009045761A1

  公开（公告）日：2009-04-09

  The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:

  本发明提供了用于治疗锌基质金属蛋白酶依赖性疾病的化合物和方法。在某些实施例中，本发明的化合物具有以下公式：
• METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT
  申请人：Jacobson Alan

  公开号：US20110190285A1

  公开（公告）日：2011-08-04

  The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V).

  本发明提供了治疗受体肉毒毒素相关疾病的方法。在某些实施例中，该方法涉及到给受体注射以下化合物：(I)、(II)、(III)、(IV)、(V)。
• COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES
  申请人：Jacobson Alan

  公开号：US20110034521A1

  公开（公告）日：2011-02-10

  The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:

  本发明提供了化合物和治疗锌基金属蛋白酶依赖性疾病的方法。在某些实施例中，本发明的化合物具有以下结构式：
• [EN] METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UNE AFFECTION LIÉE À UNE TOXINE BOTULIQUE CHEZ UN SUJET
  申请人：1 3 ABSOLUTE SCIENCE INC

  公开号：WO2010033360A1

  公开（公告）日：2010-03-25

  The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas:(I), (II), (III), (IV), (V).
• Botulinum neurotoxin serotype A inhibitors: Small-molecule mercaptoacetamide analogs
  作者：Scott T. Moe、Andrew B. Thompson、Genessa M. Smith、Ross A. Fredenburg、Ross L. Stein、Alan R. Jacobson

  DOI：10.1016/j.bmc.2009.03.013

  日期：2009.4

  Botulinum neurotoxin elicits its paralytic activity through a zinc-dependant metalloprotease that cleaves proteins involved in neurotransmitter release. Currently, no drugs are available to reverse the effects of botulinum intoxication. Herein we report the design of a novel series of mercaptoacetamide small-molecule inhibitors active against botulinum neurotoxin serotype A. These analogs show low micromolar inhibitory activity against the isolated enzyme. Structure-activity relationship studies for a series of mercaptoacetamide analogs of 5-amino-3-phenylpyrazole reveal components essential for potent inhibitory activity. (C) 2009 Elsevier Ltd. All rights reserved.